Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “IDH2 Mutation”

52 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 52 results

Large-scale testing (Phase 3)Active Not RecruitingNCT03839771
What this trial is testing

Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic Syndrome With Excess Blasts-2
Stichting Hemato-Oncologie voor Volwassenen Nederland 968
Large-scale testing (Phase 3)Looking for participantsNCT06387069
What this trial is testing

Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia
Hutchmed 316
Testing effectiveness (Phase 2)Active Not RecruitingNCT02677922
What this trial is testing

Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy

Who this might be right for
Leukemia, Myeloid, Acute
Celgene 130
Not applicableApproved For MarketingNCT05592743
What this trial is testing

Vorasidenib Expanded Access Program

Who this might be right for
GliomaRecurrenceDisease Attributes+8 more
Servier
Early research (Phase 1)UnknownNCT04806659
What this trial is testing

SH1573 Capsules in Subjects With Refractory or Relapsed Acute Myelogenous Leukemia

Who this might be right for
Acute Myelogenous Leukemia
Nanjing Sanhome Pharmaceutical, Co., Ltd. 41
Testing effectiveness (Phase 2)Active Not RecruitingNCT06478212
What this trial is testing

Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma

Who this might be right for
IDH1-mutant GliomaIDH2-mutant Glioma
Institut de Recherches Internationales Servier 51
Large-scale testing (Phase 3)Active Not RecruitingNCT06780930
What this trial is testing

Phase 3 Study of Vorasidenib (S095032/AG-881) in Asian Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 orIDH2 Mutation

Who this might be right for
Residual or Recurrent Grade 2 IDH Mutant Glioma
Servier 57
Large-scale testing (Phase 3)Active Not RecruitingNCT04164901
What this trial is testing

Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)

Who this might be right for
Grade 2 GliomaResidual GliomaRecurrent Glioma
Institut de Recherches Internationales Servier 331
Testing effectiveness (Phase 2)WithdrawnNCT03881735
What this trial is testing

Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation

Who this might be right for
Blasts Under 5 Percent of Peripheral Blood White CellsBone Marrow Blasts Decreased by 50 Percent or More Compared to Pretreatment LevelIDH2 Gene Mutation+2 more
Roswell Park Cancer Institute
Not applicableUnknownNCT04369287
What this trial is testing

Prevalence and Clinical Effect of IDH1/2 Mutations in Patients With Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid LeukemiaIDH1 Gene MutationIDH2 Gene Mutation
Istituto Clinico Humanitas 654
Testing effectiveness (Phase 2)Study completedNCT05282459
What this trial is testing

Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation

Who this might be right for
LeukemiaLeukemia, MyeloidMonocytic Leukemia
Tian Yi Zhang 17
Not applicableLooking for participantsNCT07315542
What this trial is testing

Diagnostic and Therapeutic Targets in Cartilaginous Tumours

Who this might be right for
ChondrosarcomasCartilage Tumours
St. Anne's University Hospital Brno, Czech Republic 300
Early research (Phase 1)Study completedNCT02492737
What this trial is testing

Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation

Who this might be right for
Acute Myeloid Leukemia (AML)Myelodysplastic SyndromeHematologic Malignancies
Agios Pharmaceuticals, Inc. 46
Not applicableStudy completedNCT03537560
What this trial is testing

Detection of IDH2 Mutations and Monitoring Molecular Residual Disease in Patients With AML

Who this might be right for
Acute Myeloid Leukemia
Chang Gung Memorial Hospital 334
Early research (Phase 1)Active Not RecruitingNCT04603001
What this trial is testing

Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

Who this might be right for
Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)Chronic Myelomonocytic Leukemia (CMML)+1 more
Eli Lilly and Company 260
Large-scale testing (Phase 3)Study completedNCT02577406
What this trial is testing

An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation

Who this might be right for
Leukemia, MyeloidIsocitrate Dehydrogenase
Celgene 319
Testing effectiveness (Phase 2)Active Not RecruitingNCT03212274
What this trial is testing

Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations

Who this might be right for
Advanced Malignant Solid NeoplasmGlioblastomaRecurrent Cholangiocarcinoma+4 more
National Cancer Institute (NCI) 89
Not applicableUnknownNCT02597335
What this trial is testing

Non Invasive Detection of IDH1/2 Mutation in Gliomas

Who this might be right for
GliomaIDH1/IDH2 Mutation
Assistance Publique - Hôpitaux de Paris 40
Not applicableStudy completedNCT02986620
What this trial is testing

Italian Registry on the Prevalence of IDH1/IDH2 Mutations in Patients With Acute Myeloid Leukemia

Who this might be right for
AML, Adult
Gruppo Italiano Malattie EMatologiche dell'Adulto 388
Early research (Phase 1)Looking for participantsNCT07025018
What this trial is testing

Phase I Study of HMPL-306 for the Treatment of Gliomas With IDH1 and/or IDH2 Mutations

Who this might be right for
Gliomas Harboring IDH1 and/or IDH2 Mutations
Hutchmed 52
Load More Results